Dr. Martin Kreller is a physicist and received his Ph.D. degree from Technischen Universität Dresden in 2013. He started his career in 2011 as a development engineer and Head of Development Departmnet at the Dreebit GmbH in Dresden. Dr. Martin Kreller works as research associate at the Helmoltz-Zentrum Dresden-Rossendorf since 2017 and is Head of Department in Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research (Dresden, Germany) since 2023. His research interests mainly focus on cyclotrons; radionuclide production; and solid, liquid and gas targets.

Santiago Andrés Brühlmann received his Degree in Nuclear Engineering from Instituto Balseiro (Argentina) in 2021 and is now pursuing his PhD in Chemistry at the TU Dresden (Germany). He is working at the Radiopharmaceutical Cancer Research Center of the Helmholtz-Zentrum Dresden-Rossendorf under the supervision of Dr. M. Walther, Dr. M. Kreller and Prof. Dr. K. Kopka (2021-Present). His research topics mainly include radionuclide production and purification, targetry and target chemistry.

Dr. Torsten Knieß started his career in 1994 at the Research Center Dresden-Rossendorf (Dresden, Germany) as a post-doc and became head of the Organic and Radiochemistry group in 2008 in Helmholtz-Zentrum Dresden-Rossendorf (HZDR). Since 2018, he has been responsible for the production of radiopharmaceuticals in HZDR. Dr. Knieß’s research interest mainly focuses on radiolabeling and radiopharmacy, especially on 11C- and 18F-labeled compounds (e.g. amino acids, inhibitors of tyrosine kinases and cyclooxygenase-2). Dr. Knieß’s scientific output includes 79 publications, corresponding to 1362 citations (h-index 22) (Scopus, 26 December 2023).

Prof. Dr. Klaus Kopka is a radiopharmaceutical chemist and holds a full professorship for Bioinorganic and Radiopharmaceutical Chemistry at TU Dresden, Germany, combined with the directorship of the Institute of Radiopharmaceutical Cancer Research at Helmholtz-Zentrum Dresden-Rossendorf [HZDR]. Between 2013 and 2019, he held a full professorship at Ruprecht-Karls-University of Heidelberg, Germany. At the same time, he was head of the Division of Radiopharmaceutical Chemistry at the German Cancer Research Center [DKFZ] in Heidelberg. He was involved in the development of theranostic prostate-specific membrane antigen (PSMA)-targeting radiotracers, i.e. PSMA-617 (approved as Pluvicto), and PSMA-1007 (approved as Radelumin). Prof. Kopka is a guest editor of several MDPI special issues, "Radiopharmaceutical Chemistry between Imaging and Radioendotherapy", “Emerging Theranostic Tracers in the Context of Radiopharmaceutical Drug Development”, “Forward Thinking towards Theranostic (Radio)ligands Targeting the Tumor Microenvironment (TME)”, and “Feature Reviews in Radiopharmaceutical Sciences: Highlights of Two-Decade Development”. His research interests are radiopharmaceutical drug development; radiopharmaceutical sciences; medicinal radiochemistry; radionuclide theranostics; targeted endoradiotherapy; and noninvasive molecular PET and SPECT imaging. His scientific output includes 257 publications, corresponding to 12,132 citations (h-index 55) (Scopus, 26-Dec-2023).

Dr. Martin Walther received his Ph.D. degree from Friedrich Schiller University Jena in 2002. He works as a Research Associate at the Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (2003 to present). His skills and expertise encompass radionuclide production, spectrometry, NMR spectroscopy, organic synthesis, heterocyclic chemistry, and infrared spectroscopy, as well as radiolabeling and radiometal-related expertise.